Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases

Gut microbiota exert influence on gastrointestinal mucosal permeability, bile acid metabolism, short-chain fatty acid synthesis, dietary fiber fermentation, and farnesoid X receptor/Takeda G protein-coupled receptor 5 (TGR5) signal transduction. The incretin glucagon-like peptide 1 (GLP-1) is mainly...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:mBio Ročník 15; číslo 1; s. e0203223
Hlavní autori: Zeng, Yuan, Wu, Yifan, Zhang, Qian, Xiao, Xinhua
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States American Society for Microbiology 16.01.2024
Predmet:
Bacteria
Bile
Colon
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2
Diet
Digestive system
Disease
Drugs
Enzymes
Fatty acids
Fermentation
Gastrointestinal Microbiome
Gastrointestinal surgery
Gastrointestinal tract
Genomes
Glucagon
Glucagon-like peptide 1
Glucagon-Like Peptide 1 - metabolism
Glucose
Gram-negative bacteria
Gut microbiota
Homeostasis
Hormones
Host-Microbial Interactions
Humans
Inflammation
Intestinal microflora
L cells
Membrane permeability
Metabolic disorders
Metabolites
Microbiomes
Microbiota
Microorganisms
Minireview
Obesity
Peptides
Prebiotics
Probiotics
Proteins
Signal Transduction
type 2 diabetes
Weight control
glucagon-like peptide 1
prebiotics
type 2 diabetes
gut microbiota
probiotics
ISSN:2150-7511, 2161-2129, 2150-7511
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Gut microbiota exert influence on gastrointestinal mucosal permeability, bile acid metabolism, short-chain fatty acid synthesis, dietary fiber fermentation, and farnesoid X receptor/Takeda G protein-coupled receptor 5 (TGR5) signal transduction. The incretin glucagon-like peptide 1 (GLP-1) is mainly produced by L cells in the gut and regulates postprandial blood glucose. Changes in gut microbiota composition and function have been observed in obesity and type 2 diabetes (T2D). Meanwhile, the function and rhythm of GLP-1 have also been affected in subjects with obesity or T2D. Therefore, it is necessary to discuss the link between the gut microbiome and GLP-1. In this review, we describe the interaction between GLP-1 and the gut microbiota in metabolic diseases. On the one hand, gut microbiota metabolites stimulate GLP-1 secretion, and gut microbiota affect GLP-1 function and rhythm. On the other hand, the mechanism of action of GLP-1 on gut microbiota involves the inflammatory response. Additionally, we discuss the effects and mechanism of various interventions, such as prebiotics, probiotics, antidiabetic drugs, and bariatric surgery, on the crosstalk between gut microbiota and GLP-1. Finally, we stress that gut microbiota can be used as a target for metabolic diseases, and the clinical application of GLP-1 receptor agonists should be individualized.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
The authors declare no conflict of interest.
ISSN:2150-7511
2161-2129
2150-7511
DOI:10.1128/mbio.02032-23